Zydus Lifesciences announced the publication of two manuscripts detailing the DREAM-ND and DREAM-D Phase 3 study results of Desidustat, a novel HIF-PH inhibitor in the prestigious American Journal of Nephrology.
- Read more about Zydus Lifesciences publishes phase 3 results of research molecule, Desidustat
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/zydus-lifesciences-publishes-phase-3-results-of-research-molecule-desidustat
No comments:
Post a Comment